Azenta Acquires UK Biocentre to Enhance Life Sciences Portfolio and Operational Capabilities
- Azenta acquires UK Biocentre for GBP 20.5 million to enhance its life sciences operations in the UK.
- The acquisition aims to improve service delivery and operational efficiencies for clients across Europe.
- Azenta focuses on integrating UK Biocentre's expertise to advance research and innovation in the life sciences sector.
Azenta Expands Its Life Sciences Portfolio with Acquisition of UK Biocentre
Azenta, Inc., a leader in life science solutions, makes a significant advancement in its operational capabilities by acquiring UK Biocentre Limited for GBP 20.5 million. This acquisition, which is carried out through Azenta's subsidiary Azenta UK Ltd, aims to solidify the company’s position in the UK—an essential hub for life sciences research—and enhance its end-to-end lifecycle solutions. By incorporating UK Biocentre, recognized for its expertise in sample management, storage, and high-throughput processing, Azenta seeks to bolster its support for pharmaceutical, biotechnology, academic, and public health clients across Europe.
Founded in 2014, UK Biocentre has generated substantial revenues, amounting to approximately GBP 15.3 million for the year ending September 30, 2025. With this acquisition, Azenta strategically positions itself to reap operational efficiencies and improve its service delivery across the continent. The deal includes an additional contingent consideration of up to GBP 1.8 million depending on specific performance milestones, reflecting Azenta's commitment to a successful integration that aligns with future growth objectives. Although the integration may slightly impact Azenta's Adjusted EBITDA margins in the short term for 2026, the long-term outlook remains optimistic, anticipating notable gains in organic revenue and EBITDA margins by 2027 and 2028.
John Marotta, Azenta's President and CEO, emphasizes that the acquisition is not just about expansion but also enhancing the company's overall operational capabilities. The integration aligns with Azenta's broader strategy to introduce cutting-edge biorepository technologies, including the innovative 16-million-sample BioArc™ Ultra. By having UK Biocentre continue its operations under its existing brand, Azenta reaffirms its commitment to maintaining scientific excellence and innovation in the sector. This merger is projected to create synergies that bolster both organizations' strengths, reinforcing Azenta's leadership in the life sciences landscape and streamlining critical workflows essential for advancing research efforts.
In addition to the acquisition, Azenta's commitment to sustainable and efficient practices continues to shape its business model. This acquisition not only reflects strategic growth but also positions the company to better serve its clients in a rapidly evolving market. As Azenta integrates UK Biocentre’s capabilities, it paves the way for enhanced service offerings that may spur further developments in life sciences and healthcare innovation throughout Europe.
Overall, the acquisition of UK Biocentre marks a pivotal moment in Azenta's growth trajectory, with promising implications for its operational effectiveness and client engagement across the continent.